An Open-label, Single-Arm Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein